Monthly Archives: October 2023

Tirzepatide significant and superior weight loss Drug

Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies INDIANAPOLIS, July 27, 2023. Eli Lilly announced results of Mounjaro (tirzepatide) phase 3 studies in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes. SURMOUNT-3 and SURMOUNT-4 met all primary and key secondary objectives for tirzepatide compared to placebo. Across […]